The Efficacy and Safety of TACE Combined With Arginine Hydrochloride and Trimetazidine Hydrochloride Tablets in With Hepatocellular Carcinoma. A Multicenter, Open, Randomized, Prospective Study (TIHCC)

NCT03274427 Phase 3 UNKNOWN

The purpose of this study is to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with arginine hydrochloride and trimetazidine hydrochloride tablets in the treatment of patients with hepatocellular carcinoma.

Details

Lead sponsor	The First Affiliated Hospital of Zhengzhou University
Phase	Phase 3
Status	UNKNOWN
Enrolment	300
Start date	2017-07-18
Completion	2021-07

Conditions

• HCC

Interventions

• Basic drugs therapy of HCC by TACE
• Arginine hydrochloride
• Trimetazidine hydrochloride

Primary outcomes

• Progression-free Survival — 24 months
  Time from start of treatment until the first documented event of symptomatic progression or death.

Countries

China